CDC warns access to ADHD meds may be disrupted after arrests of health-care startup executives
CNN
People taking medications for ADHD, or attention-deficit hyperactivity disorder, may face disruptions in accessing treatment after the arrests of two executives of a telehealth company that distributed such drugs to adults across the United States.
People taking medications for ADHD, or attention-deficit hyperactivity disorder, may face disruptions in accessing treatment after the arrests of two executives of a telehealth company that distributed such drugs to adults across the United States. On Thursday, the US Centers for Disease Control and Prevention issued an official health advisory warning about a “potential disrupted access to care among individuals taking prescription stimulant medications and possible increased risks for injury and overdose.” Around the same time, the US Department of Justice announced a federal health-care fraud indictment against two executives from the digital health company Done Global, whose website describes it as “making high quality psychiatric chronic care management more accessible and affordable for patients.” The indictment’s effect on patients “is unknown at the time,” according to the CDC’s advisory. “Patients who rely on prescription stimulant medications to treat their ADHD and have been using this or other similar subscription-based telehealth platforms could experience a disruption to their treatment and disrupted access to care,” the advisory said. “A disruption involving this large telehealth company could impact as many as 30,000 to 50,000 patients ages 18 years and older across all 50 U.S. states.” Ruthia He, the founder and CEO of Done Global Inc., was arrested in Los Angeles on Thursday and accused of participating in a scheme to distribute Adderall over the internet, conspire to commit health-care fraud and obstruct justice, according to the Justice Department’s announcement. The company’s clinical president, David Brody, also was arrested in San Rafael, California.
